Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

GlaxoSmithKline Initiates Head-to-Head Study of Cervical Cancer Vaccines

18.01.2007
Study to Compare Immunogencity of GSK's Cervical Cancer Candidate Vaccine, CERVARIX(R), to Merck's Gardasil(R)

GlaxoSmithKline (NYSE: GSK) announced today the initiation of the first study of its kind designed to compare the immunogenicity of its cervical cancer candidate vaccine, CERVARIX(R), versus Gardasil(R). The primary objective of the head-to-head trial is to compare the immune responses to HPV types 16 and 18 in U.S. women 18 to 26-years-old. Secondary objectives include evaluating the immune responses to HPV 16 and 18 in women 27 to 35-years-old and 36 to 45-years-old. In addition, the study will compare immune responses to other cancer-causing HPV types. Initial study results are anticipated 12 months after study enrollment is completed, and extended follow up will continue for another 17 months.

"Vaccination to prevent cervical cancer may be the most significant healthcare breakthrough for women in our lifetime," said Dr. Mark M. Blatter, Medical Director of Primary Physicians Research in Pittsburgh, PA and study investigator. "This unprecedented trial, which will enroll more than 1,000 women, will provide the first scientific evidence to demonstrate how the two vaccines differ with respect to inducing strong and sustained immune responses in women who may be appropriate for vaccination."

Data published in Vaccine in August 2006 demonstrated GSK's cervical candidate vaccine, formulated with the proprietary adjuvant system AS04, induced higher antibody levels and more robust immune memory response compared to the same HPV vaccine composition conventionally formulated with aluminium hydroxide adjuvant alone. Furthermore, data published in The Lancet in April 2006 provided evidence that GSK's cervical cancer candidate vaccine demonstrated protection up to 4.5 years against persistent infection with HPV 16 and HPV 18 - the two most common cancer-causing HPV types - and protection from pre-cancerous lesions. Protection was also demonstrated against infection with the third and fourth most prevalent cancer-causing types of HPV, namely types 45 and 31. Collectively, HPV types 16, 18, 45 and 31 are responsible for approximately 80 percent of cervical cancer cases globally.

"GSK is focused on protecting women from cervical cancer, a devastating disease that often strikes women in the prime of their lives," said Gary Dubin, Vice President, HPV Vaccines, GlaxoSmithKline. "By conducting this study, we hope to further the scientific understanding of the role of strong and sustained immune responses to HPV vaccination for the benefit of all women."

About the Study

This is a Phase III, randomized, observer-blind, multicenter study, to be conducted among 1,042 patients in the United States. There will be two arms of the study, one arm receiving GSK's cervical cancer candidate vaccine, one arm receiving Gardasil(R), and each arm will be stratified by age (18-26 [n=374], 27-35 [n=334], 36-45 [n=334]). The primary objective of the study is to compare GSK's cervical cancer candidate vaccine to Gardasil(R), in terms of immune responses to the two most common cancer-causing HPV types 16 and 18, which are responsible for at least 70 percent of all cervical cancers worldwide, in adult women aged 18 to 26. Secondary objectives will assess immune responses to cancer-causing HPV types 16 and 18 in adult women aged 27 to 35, and 36 to 45 as well as evaluate immune responses to other cancer-causing HPV types. Results are expected 12 months after patient enrollment is complete, with extended follow up continuing for approximately 17 months after the last study visit (month 7 through month 24).

About Cervical Cancer

The American Cancer Society estimates that in 2006, nearly 10,000 women were diagnosed with cervical cancer and nearly 4,000 died from this disease in the Unites States in a single year. After breast cancer, cervical cancer is the second most frequently occurring cancer in women ages 20 to 39 in the United States.

About GlaxoSmithKline's Cervical Cancer Candidate Vaccine

GSK's cervical cancer candidate vaccine was developed to prevent infection and lesions from the two most prevalent cancer-causing types of HPV, specifically HPV 16 and 18. It is formulated with the proprietary adjuvant system, AS04, selected to ensure that this vaccine confers strong and sustained antibody levels over time.

More than 16,000 women worldwide have been vaccinated with GSK's cervical cancer candidate vaccine as part of completed and ongoing clinical trials. Phase III studies are under way in more than 25 countries with more than 35,000 subjects enrolled in ongoing trials.

GSK plans to file a biologics license application for CERVARIX(R) for U.S. Food and Drug Administration review by April in 2007 for its cervical cancer candidate vaccine. The company submitted a marketing application review to the European Agency for the Evaluation of Medicinal Products in March 2006. Other international regulatory filings followed in Australia, parts of Asia and parts of Latin America in March 2006.

About GlaxoSmithKline

In the next two to five years, GSK expects to launch more major new vaccines in the United States, for example, a vaccine against rotavirus, an improved flu vaccine for the elderly and a meningitis combination vaccines for various ages, including infants.

GlaxoSmithKline-one of the world's leading research-based pharmaceutical and healthcare companies-is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, please visit www.gsk.com.

GSK Biologicals (GSK Bio), one of the world's leading vaccine manufacturers, is headquartered in Rixensart, Belgium, where the majority of GlaxoSmithKline's activities in the field of vaccine research, development and production are conducted. GSK Bio employs more than 1,500 scientists, who are devoted to discovering new vaccines and developing more cost-effective and convenient combination products to prevent infections that cause serious medical problems worldwide. In 2005, GSK Bio distributed more than 1.2 billion doses of vaccines to 165 countries in both the developed and the developing world, an average of more than 3 million doses per day.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the 'Operating and Financial Review and Prospects' in the company's Annual Report on Form 20-F for 2005.

Danielle Halstrom | presseportal
Further information:
http://www.gsk.com

More articles from Studies and Analyses:

nachricht Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung

nachricht Scientists reveal source of human heartbeat in 3-D
07.08.2017 | University of Manchester

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>